Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Definitive agreement under which BMS acquires all outstanding Adnexus shares for $430M gross / $415M net; Adnectins biologics platform a core strategic…
Adnexus adopted monobody technology commercially as Adnectins; BMS acquired Adnexus in 2007, making the Adnectin scaffold a core BMS biologics platform.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$430M cash + up to $75M earnout. Adnectins biologics platform; Angiocept Phase I. Source: SEC, Fierce Biotech, WilmerHale.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Adnexus Therapeutics Inc. (this deal) | 2007 | $430M | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |